New drug combo for borderline or locally advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a combination of two investigational drugs (nogapendekin alfa inbakicept and sotevtamab) plus zabadinostat alongside standard chemotherapy (gemcitabine and nab-paclitaxel) before surgery. It is for people whose pancreatic cancer is either borderline resectable (surgery is possible but tricky) or locally advanced (surgery isn't currently an option). The goal is to see if this approach can shrink the tumor enough to allow surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer) that is limited to the pancreas.
- Your cancer is considered borderline resectable or locally advanced (your doctor has determined surgery is possible but challenging, or not possible right now).
- You have not had any prior treatment for your pancreatic cancer.
- You are generally in good health, able to perform daily activities without significant help (ECOG score 0 or 1).
- You have measurable tumors that can be tracked on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—atebimetinib (a new targeted therapy), gemcitabine, and nab-paclitaxel (two standard chemotherapy drugs)—as a first treatment for pancreatic cancer that has spread beyond the pancreas. The goal is to see if adding atebimetinib helps patients live longer and feel better.
This trial tests a combination of immunotherapy (PD-1), chemotherapy, and a special type of radiation called PULSAR for patients with locally advanced pancreatic cancer or cancer that has come back only in the pancreas area. The goal is to see if this approach can shrink tumors or keep them from growing.
This trial tests a new drug combination for people whose pancreatic cancer has grown after their first treatment. The goal is to see if it can help shrink tumors or slow the disease.
This trial tests a new combination of drugs (TQB2868 injection plus anlotinib capsules) compared to standard chemotherapy for people with pancreatic cancer that has spread to other parts of the body and has not been treated before.
This trial tests a new drug (BMS-986340) plus standard chemo for people whose pancreatic cancer has spread or come back. The goal is to see if this combination works better.
This trial tests a combination of three drugs (gemcitabine, erlotinib, and nab-paclitaxel) for people with a specific type of pancreatic cancer called 'basal-like' PDAC. It aims to see if this targeted approach works better than standard treatment.
Hear when a new Pancreatic Cancer Resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.